HKG: 0806

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million Series E financing round. The round was led by a private equity fund of Value Partners Group (HKG: 0806), with participation from Shanghai Pudong Venture Investment, Shanghai Pudong Development (Group), Wuxi Innovation Investment, and Yixing…